These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7790175)

  • 21. Some aspects on the management of hemophilia.
    Aledort LM
    Thromb Haemost; 1995 Jul; 74(1):440-3. PubMed ID: 8578502
    [No Abstract]   [Full Text] [Related]  

  • 22. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs of care in hemophilia and possible implications of health care reform.
    Johnson KA; Zhou ZY
    Hematology Am Soc Hematol Educ Program; 2011; 2011():413-8. PubMed ID: 22160067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study.
    Shapiro AD; Donfield SM; Lynn HS; Cool VA; Stehbens JA; Hunsberger SL; Tonetta S; Gomperts ED;
    Pediatrics; 2001 Dec; 108(6):E105. PubMed ID: 11731632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A patient's perspective on hemophilia.
    Sulser E
    Semin Hematol; 2006 Apr; 43(2 Suppl 3):S13-6. PubMed ID: 16631822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.
    McMullen S; Buckley B; Hall E; Kendter J; Johnston K
    Value Health; 2017 Jan; 20(1):93-99. PubMed ID: 28212975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health economic models in hemophilia A and utility assumptions from a clinician's perspective.
    Valente M; Cortesi PA; Lassandro G; Mathew P; Pocoski J; Molinari AC; Mantovani LG; Giordano P
    Pediatr Blood Cancer; 2015 Oct; 62(10):1826-31. PubMed ID: 25976056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
    Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
    Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
    Lorenzoni V; Triulzi I; Turchetti G
    BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemophilia in the managed care setting.
    Dalton DR
    Am J Manag Care; 2015 Mar; 21(6 Suppl):S123-30. PubMed ID: 26168207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis for a tele-based health coaching program for chronic disease in primary care.
    Oksman E; Linna M; Hörhammer I; Lammintakanen J; Talja M
    BMC Health Serv Res; 2017 Feb; 17(1):138. PubMed ID: 28202032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing outcomes for patients with severe haemophilia A.
    Pipe SW; Valentino LA
    Haemophilia; 2007 Nov; 13 Suppl 4():1-16; quiz 3 p following 16. PubMed ID: 17822512
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(1):19-25. PubMed ID: 7796372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit.
    Roosendaal G; Lafeber F
    N Engl J Med; 2007 Aug; 357(6):603-5. PubMed ID: 17687136
    [No Abstract]   [Full Text] [Related]  

  • 36. A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home.
    Gardulf A; Möller G; Jonsson E
    Int J Technol Assess Health Care; 1995; 11(2):345-53. PubMed ID: 7540602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Social/economic costs and quality of life in patients with haemophilia in Europe.
    Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Gulácsi L; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():53-65. PubMed ID: 27048374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Home treatment in hemophilia].
    Pabinger I; Niessner H; Korninger C; Nowotny C; Stain M; Kyrle PA; Lechner K
    Wien Klin Wochenschr; 1987 Nov; 99(22):773-7. PubMed ID: 3124354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
    Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
    Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.